Home
AI Agent
Annotations
Files

Pricing and plans
Get the full experience
We save the real magic for signed-in users.

Home Stock Screener Document Search Charting Watchlists Recent Filings

ImmunityBio, Inc.(IBRX US)

$6.02-0.050.82%Ext:$6.01-0.010.17%(Market Closed · 00:59:53 UTC)

Doc Search Profile Entity StructureFinancials Charting Short Interest Employees

Overview

Profile Entity Structure

Documents

Categorized Chronological By Owner

Financials & Metrics

Financials Charting Short Interest Employees

Home
AI Agent
Annotations
Files

Pricing and plans
Get the full experience
We save the real magic for signed-in users.

Home Stock Screener Document Search Charting Watchlists Recent Filings

ImmunityBio, Inc.(IBRX US)

$6.02-0.050.82%Ext:$6.01-0.010.17%(Market Closed · 00:59:53 UTC)

Doc Search Profile Entity StructureFinancials Charting Short Interest Employees

Overview

Profile Entity Structure

Documents

Categorized Chronological By Owner

Financials & Metrics

Financials Charting Short Interest Employees

IBRX US

IBRX US

Chronological SEC Filings

Chronological SEC Filings

Non-Ownership Filings(267)

10-QQ3ended 30 Sept 20269 Nov
8-KResults of Operations and Financial Condition9 Nov
8-KRegulation FD Disclosure9 Nov
8-KFDA Expands ANKTIVA®Approval forBCG-UnresponsiveNon-Muscle-Invasive Bladder Cancer to Cover Both Papillary and CIS Disease14 Oct
10-QQ2ended 30 Jun 20264 Aug
8-KResults of Operations and Financial Condition4 Aug
8-KRegulation FD Disclosure30 Jul
8-KSubmission of Matters to a Vote of Security Holders10 Jun
8-KImmunityBio Signs Exclusive U.S. Agreement with Japan BCG Laboratory for the Tokyo Strain of BCG to Enhance BCG Supply in the United States18 May
10-QQ1ended 31 Mar 20267 May
8-KResults of Operations and Financial Condition7 May
DEFA14ADefinitive additional materials29 Apr
DEF 14ADefinitive proxy statement29 Apr
ARSAnnual report to security holders29 Apr
8-KResults of Operations and Financial Condition9 Apr
8-KImmunityBio Addresses FDA Correspondence and Reaffirms Commitment to Advertising Compliance6 Apr
8-KImmunityBio Strengthens Balance Sheet with $100 Million of Financing Transactions Including $75 Million ofNon-DilutiveFinancing to Support Global Expansion and Advancement of Broader Immunotherapy Pipeline31 Mar
10-KFY 2025ended 31 Dec 202523 Feb
8-KResults of Operations and Financial Condition23 Feb
8-KOther Events18 Feb

Ownership Filings(281)

Form 4Simon Barry J.6 Oct
Form 4Cohen Cheryl6 Oct
Form 144Simon Barry J.5 Oct
Form 144Cohen Cheryl2 Oct
SC 13D/AImmunityBio, Inc.6 Aug
Form 4Cohen Cheryl6 Jul
Form 4Selecky Christobel6 Jul
Form 144Cohen Cheryl2 Jul
Form 4Selecky Christobel1 Jul
Form 144Selecky Christobel1 Jul
Form 144Selecky Christobel30 Jun
Form 144Selecky Christobel29 Jun
Form 4Simon Barry J.26 Jun
Form 4BLASZYK MICHAEL D10 Jun
Form 4Wendel Bruce10 Jun
Form 4MAXWELL LINDA10 Jun
Form 4Clark Wesley10 Jun
Form 4Cohen Cheryl10 Jun
Form 4Selecky Christobel10 Jun
Form 4Simon Barry J.5 Jun

Non-Ownership Filings(267)

10-QQ3ended 30 Sept 20269 Nov
8-KResults of Operations and Financial Condition9 Nov
8-KRegulation FD Disclosure9 Nov
8-KFDA Expands ANKTIVA®Approval forBCG-UnresponsiveNon-Muscle-Invasive Bladder Cancer to Cover Both Papillary and CIS Disease14 Oct
10-QQ2ended 30 Jun 20264 Aug
8-KResults of Operations and Financial Condition4 Aug
8-KRegulation FD Disclosure30 Jul
8-KSubmission of Matters to a Vote of Security Holders10 Jun
8-KImmunityBio Signs Exclusive U.S. Agreement with Japan BCG Laboratory for the Tokyo Strain of BCG to Enhance BCG Supply in the United States18 May
10-QQ1ended 31 Mar 20267 May
8-KResults of Operations and Financial Condition7 May
DEFA14ADefinitive additional materials29 Apr
DEF 14ADefinitive proxy statement29 Apr
ARSAnnual report to security holders29 Apr
8-KResults of Operations and Financial Condition9 Apr
8-KImmunityBio Addresses FDA Correspondence and Reaffirms Commitment to Advertising Compliance6 Apr
8-KImmunityBio Strengthens Balance Sheet with $100 Million of Financing Transactions Including $75 Million ofNon-DilutiveFinancing to Support Global Expansion and Advancement of Broader Immunotherapy Pipeline31 Mar
10-KFY 2025ended 31 Dec 202523 Feb
8-KResults of Operations and Financial Condition23 Feb
8-KOther Events18 Feb

Ownership Filings(281)

Form 4Simon Barry J.6 Oct
Form 4Cohen Cheryl6 Oct
Form 144Simon Barry J.5 Oct
Form 144Cohen Cheryl2 Oct
SC 13D/AImmunityBio, Inc.6 Aug
Form 4Cohen Cheryl6 Jul
Form 4Selecky Christobel6 Jul
Form 144Cohen Cheryl2 Jul
Form 4Selecky Christobel1 Jul
Form 144Selecky Christobel1 Jul
Form 144Selecky Christobel30 Jun
Form 144Selecky Christobel29 Jun
Form 4Simon Barry J.26 Jun
Form 4BLASZYK MICHAEL D10 Jun
Form 4Wendel Bruce10 Jun
Form 4MAXWELL LINDA10 Jun
Form 4Clark Wesley10 Jun
Form 4Cohen Cheryl10 Jun
Form 4Selecky Christobel10 Jun
Form 4Simon Barry J.5 Jun